JP2010529969A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010529969A5 JP2010529969A5 JP2010511510A JP2010511510A JP2010529969A5 JP 2010529969 A5 JP2010529969 A5 JP 2010529969A5 JP 2010511510 A JP2010511510 A JP 2010511510A JP 2010511510 A JP2010511510 A JP 2010511510A JP 2010529969 A5 JP2010529969 A5 JP 2010529969A5
- Authority
- JP
- Japan
- Prior art keywords
- ethylamino
- alkyl
- butoxyphenyl
- compound
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 46
- 229910052739 hydrogen Inorganic materials 0.000 claims description 39
- 239000001257 hydrogen Substances 0.000 claims description 39
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 32
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 17
- 150000003839 salts Chemical class 0.000 claims description 14
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 8
- 230000003287 optical effect Effects 0.000 claims description 8
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 6
- 125000005842 heteroatom Chemical group 0.000 claims description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 6
- 150000002431 hydrogen Chemical group 0.000 claims description 5
- 125000003143 4-hydroxybenzyl group Chemical group [H]C([*])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 16
- 208000035475 disorder Diseases 0.000 claims 16
- -1 2- [2- (3-butoxyphenyl) -ethylamino] -N-methylacetamide 2- [2- (3-pentyloxyphenyl) -ethylamino] -N-methylacetamide 2- [2- ( 3-hexyloxyphenyl) -ethylamino] -N-methylacetamide Chemical compound 0.000 claims 11
- 239000003814 drug Substances 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 230000002401 inhibitory effect Effects 0.000 claims 8
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 6
- 208000012902 Nervous system disease Diseases 0.000 claims 6
- 208000002193 Pain Diseases 0.000 claims 6
- 208000010877 cognitive disease Diseases 0.000 claims 6
- 229940124597 therapeutic agent Drugs 0.000 claims 6
- 108090000312 Calcium Channels Proteins 0.000 claims 5
- 102000003922 Calcium Channels Human genes 0.000 claims 5
- 230000001149 cognitive effect Effects 0.000 claims 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 4
- 206010015037 epilepsy Diseases 0.000 claims 4
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 claims 4
- 208000020016 psychiatric disease Diseases 0.000 claims 4
- 239000011734 sodium Substances 0.000 claims 4
- 229910052708 sodium Inorganic materials 0.000 claims 4
- 125000006530 (C4-C6) alkyl group Chemical group 0.000 claims 3
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims 3
- GRHBODILPPXVKN-UHFFFAOYSA-N 2-[2-(3-butoxyphenyl)ethylamino]-n,n-dimethylacetamide Chemical compound CCCCOC1=CC=CC(CCNCC(=O)N(C)C)=C1 GRHBODILPPXVKN-UHFFFAOYSA-N 0.000 claims 3
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 3
- 208000025609 Urogenital disease Diseases 0.000 claims 3
- 230000000561 anti-psychotic effect Effects 0.000 claims 3
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 230000002757 inflammatory effect Effects 0.000 claims 3
- 229940098779 methanesulfonic acid Drugs 0.000 claims 3
- 230000000926 neurological effect Effects 0.000 claims 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 3
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- 201000006474 Brain Ischemia Diseases 0.000 claims 2
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 2
- 208000019695 Migraine disease Diseases 0.000 claims 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims 2
- 208000025966 Neurological disease Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 208000028017 Psychotic disease Diseases 0.000 claims 2
- 208000005793 Restless legs syndrome Diseases 0.000 claims 2
- 108010052164 Sodium Channels Proteins 0.000 claims 2
- 102000018674 Sodium Channels Human genes 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 206010008118 cerebral infarction Diseases 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 229960003878 haloperidol Drugs 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 206010027599 migraine Diseases 0.000 claims 2
- 208000027061 mild cognitive impairment Diseases 0.000 claims 2
- 125000002950 monocyclic group Chemical group 0.000 claims 2
- 230000001575 pathological effect Effects 0.000 claims 2
- 230000007170 pathology Effects 0.000 claims 2
- 230000008844 regulatory mechanism Effects 0.000 claims 2
- 229960001534 risperidone Drugs 0.000 claims 2
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 1
- 125000006531 (C2-C5) alkyl group Chemical group 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- HZDDXUQXCXKUAR-UHFFFAOYSA-N 2-[2-(3-butoxyphenyl)ethylamino]-3-hydroxy-n,n-dimethylpropanamide Chemical compound CCCCOC1=CC=CC(CCNC(CO)C(=O)N(C)C)=C1 HZDDXUQXCXKUAR-UHFFFAOYSA-N 0.000 claims 1
- GNZSOXBPRNHNGO-UHFFFAOYSA-N 2-[2-(3-butoxyphenyl)ethylamino]-3-methoxy-n,n-dimethylpropanamide Chemical compound CCCCOC1=CC=CC(CCNC(COC)C(=O)N(C)C)=C1 GNZSOXBPRNHNGO-UHFFFAOYSA-N 0.000 claims 1
- IRPKKGLOGMXKDX-UHFFFAOYSA-N 2-[2-(3-butoxyphenyl)ethylamino]-N,N-dibutylacetamide N,N-dimethyl-2-[2-(3-pentoxyphenyl)ethylamino]acetamide Chemical compound CCCCCOC1=CC=CC(CCNCC(=O)N(C)C)=C1.CCCCOC1=CC=CC(CCNCC(=O)N(CCCC)CCCC)=C1 IRPKKGLOGMXKDX-UHFFFAOYSA-N 0.000 claims 1
- DXNSJWVLSBMXNR-UHFFFAOYSA-N 2-[2-(3-butoxyphenyl)ethylamino]-n,n-dimethylacetamide;hydrochloride Chemical compound Cl.CCCCOC1=CC=CC(CCNCC(=O)N(C)C)=C1 DXNSJWVLSBMXNR-UHFFFAOYSA-N 0.000 claims 1
- UGYMDVZYADOSEF-UHFFFAOYSA-N 2-[2-(3-butoxyphenyl)ethylamino]-n,n-dimethylpropanamide Chemical compound CCCCOC1=CC=CC(CCNC(C)C(=O)N(C)C)=C1 UGYMDVZYADOSEF-UHFFFAOYSA-N 0.000 claims 1
- KEPMAXZCFQLVCV-UHFFFAOYSA-N 2-[2-(3-butoxyphenyl)ethylamino]acetamide;2-[2-(3-hexoxyphenyl)ethylamino]acetamide;2-[2-(3-pentoxyphenyl)ethylamino]acetamide Chemical compound CCCCOC1=CC=CC(CCNCC(N)=O)=C1.CCCCCOC1=CC=CC(CCNCC(N)=O)=C1.CCCCCCOC1=CC=CC(CCNCC(N)=O)=C1 KEPMAXZCFQLVCV-UHFFFAOYSA-N 0.000 claims 1
- IMFFKOWDBWQFOM-UHFFFAOYSA-N 2-[2-(3-hexoxyphenyl)ethylamino]-n,n-dimethylacetamide Chemical compound CCCCCCOC1=CC=CC(CCNCC(=O)N(C)C)=C1 IMFFKOWDBWQFOM-UHFFFAOYSA-N 0.000 claims 1
- HMIQHDRVKGLRRK-UHFFFAOYSA-N 2-[2-[3-butoxy-5-(trifluoromethyl)phenyl]ethylamino]-n,n-dimethylacetamide Chemical compound CCCCOC1=CC(CCNCC(=O)N(C)C)=CC(C(F)(F)F)=C1 HMIQHDRVKGLRRK-UHFFFAOYSA-N 0.000 claims 1
- UOUSPOHEYLJZJG-UHFFFAOYSA-N C(CCC)OC=1C=C(C=CC1)CCNCC(=O)N(CCC)CCC.C(CCC)OC=1C=C(C=CC1)CCNCC(=O)N(CC)CC.C(CCC)OC=1C=C(C=CC1OC)CCNCC(=O)N(C)C Chemical compound C(CCC)OC=1C=C(C=CC1)CCNCC(=O)N(CCC)CCC.C(CCC)OC=1C=C(C=CC1)CCNCC(=O)N(CC)CC.C(CCC)OC=1C=C(C=CC1OC)CCNCC(=O)N(C)C UOUSPOHEYLJZJG-UHFFFAOYSA-N 0.000 claims 1
- MBQVGFDQYDCDLJ-QZCDQQELSA-N C(CCC)OC=1C=C(C=CC1)CCN[C@H](C(=O)NC)C.C(CCC)OC=1C=C(C=CC1)CCN[C@H](C(=O)N)C.C(CCCCC)OC=1C=C(C=CC1)CCNC(C(=O)N(C)C)(C)C Chemical compound C(CCC)OC=1C=C(C=CC1)CCN[C@H](C(=O)NC)C.C(CCC)OC=1C=C(C=CC1)CCN[C@H](C(=O)N)C.C(CCCCC)OC=1C=C(C=CC1)CCNC(C(=O)N(C)C)(C)C MBQVGFDQYDCDLJ-QZCDQQELSA-N 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 208000016192 Demyelinating disease Diseases 0.000 claims 1
- 206010052804 Drug tolerance Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 102000016913 Voltage-Gated Sodium Channels Human genes 0.000 claims 1
- 108010053752 Voltage-Gated Sodium Channels Proteins 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- 230000002917 arthritic effect Effects 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 229960004170 clozapine Drugs 0.000 claims 1
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 208000010643 digestive system disease Diseases 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 210000000750 endocrine system Anatomy 0.000 claims 1
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 230000026781 habituation Effects 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 210000002346 musculoskeletal system Anatomy 0.000 claims 1
- VRLSELRYHHSXAL-UHFFFAOYSA-N n,n-dimethyl-2-[2-(3-pentoxyphenyl)ethylamino]acetamide Chemical compound CCCCCOC1=CC=CC(CCNCC(=O)N(C)C)=C1 VRLSELRYHHSXAL-UHFFFAOYSA-N 0.000 claims 1
- PEFUSHFQQPUGQX-UHFFFAOYSA-N n,n-dimethyl-2-[2-[3-(4,4,4-trifluorobutoxy)phenyl]ethylamino]acetamide Chemical compound CN(C)C(=O)CNCCC1=CC=CC(OCCCC(F)(F)F)=C1 PEFUSHFQQPUGQX-UHFFFAOYSA-N 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 150000003254 radicals Chemical class 0.000 claims 1
- 210000002345 respiratory system Anatomy 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07011766.8 | 2007-06-15 | ||
| EP07011766 | 2007-06-15 | ||
| PCT/EP2008/003848 WO2008151702A1 (en) | 2007-06-15 | 2008-05-14 | Substituted 2- [2- (phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010529969A JP2010529969A (ja) | 2010-09-02 |
| JP2010529969A5 true JP2010529969A5 (enExample) | 2012-06-07 |
| JP5440496B2 JP5440496B2 (ja) | 2014-03-12 |
Family
ID=38658156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010511510A Active JP5440496B2 (ja) | 2007-06-15 | 2008-05-14 | 置換２−［２−（フェニル）エチルアミノ］アルカンアミド誘導体ならびにナトリウムおよび／またはカルシウムチャネル調節剤としてのこれらの使用 |
Country Status (27)
| Country | Link |
|---|---|
| US (8) | US8519000B2 (enExample) |
| EP (1) | EP2155663B1 (enExample) |
| JP (1) | JP5440496B2 (enExample) |
| KR (1) | KR101545124B1 (enExample) |
| CN (1) | CN101687773B (enExample) |
| AR (1) | AR068976A1 (enExample) |
| AU (1) | AU2008261325B2 (enExample) |
| BR (1) | BRPI0813363B8 (enExample) |
| CA (1) | CA2689561C (enExample) |
| CY (1) | CY1119787T1 (enExample) |
| DK (1) | DK2155663T3 (enExample) |
| EA (1) | EA018195B1 (enExample) |
| ES (1) | ES2655704T3 (enExample) |
| HR (1) | HRP20180324T8 (enExample) |
| HU (1) | HUE038113T2 (enExample) |
| IL (1) | IL202235A (enExample) |
| LT (1) | LT2155663T (enExample) |
| MX (1) | MX2009013119A (enExample) |
| NO (1) | NO2155663T3 (enExample) |
| NZ (1) | NZ581288A (enExample) |
| PL (1) | PL2155663T3 (enExample) |
| PT (1) | PT2155663T (enExample) |
| RS (1) | RS56780B1 (enExample) |
| SI (1) | SI2155663T1 (enExample) |
| TR (1) | TR201802576T4 (enExample) |
| TW (1) | TWI400071B (enExample) |
| WO (1) | WO2008151702A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004266494B2 (en) * | 2003-08-25 | 2010-04-08 | Newron Pharmaceuticals, Spa | Alpha-aminoamide derivatives useful as anti-inflammatory agents |
| JP5213265B2 (ja) * | 2009-10-08 | 2013-06-19 | 花王株式会社 | Ｌｏｘ−１発現調節剤の評価又は選択方法 |
| AU2012278193B2 (en) | 2011-06-27 | 2017-03-30 | Newron Pharmaceuticals S.P.A. | Fluorinated arylalkylaminocarboxamide derivatives |
| CN103804341B (zh) * | 2012-11-13 | 2018-04-10 | 中国人民解放军军事医学科学院毒物药物研究所 | 酰胺衍生物及其医药用途 |
| CN104761531B (zh) * | 2014-01-03 | 2017-12-01 | 中国人民解放军军事医学科学院毒物药物研究所 | 镇痛活性化合物及其医药用途 |
| NZ742033A (en) * | 2015-11-12 | 2022-11-25 | Afasci Inc | Ion channel inhibitory compounds, pharmaceutical formulations and uses |
| CN106316824B (zh) * | 2016-08-18 | 2018-10-19 | 广州康瑞泰药业有限公司 | 一种合成2-氟环丙烷甲酸的新方法 |
| WO2019205147A1 (zh) * | 2018-04-28 | 2019-10-31 | 上海璃道医药科技有限公司 | 包含苯并含氧脂肪环结构的氨基乙酰胺类化合物及其用途 |
| DE112019004296T5 (de) * | 2018-08-30 | 2021-07-22 | Sabic Global Technologies B.V. | Aromatisierungskatalysator mit verbesserter isomerisierung, herstellungsverfahren und verwendung davon |
| EP3725769A1 (en) * | 2019-04-17 | 2020-10-21 | Newron Pharmaceuticals S.p.A. | Process for the production of substituted 2-[2-(phenyl) ethylamino]alkaneamide derivatives |
| EP3725768A1 (en) | 2019-04-17 | 2020-10-21 | Newron Pharmaceuticals S.p.A. | Process for the production of substituted 2-[2-(phenyl) ethylamino]alkaneamide derivatives |
| TW202448849A (zh) | 2023-04-28 | 2024-12-16 | 義大利商紐隆製藥公司 | 依維那胺(evenamide)之晶形 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB586645A (en) * | 1944-07-19 | 1947-03-26 | Burroughs Wellcome Co | Improvements relating to the synthesis of amino acid derivatives and salts thereof |
| GB1254332A (en) * | 1969-02-27 | 1971-11-17 | Science Union & Cie | Amino acids and their derivatives and processes for preparing them |
| IL94466A (en) * | 1989-05-25 | 1995-01-24 | Erba Carlo Spa | Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation |
| US5051403A (en) * | 1989-11-22 | 1991-09-24 | Neurex Corporation | Method of treating ischemia-related neuronal damage |
| DE69225499T2 (de) * | 1991-12-30 | 1999-02-04 | Neurex Corp., Menlo Park, Calif. | Methoden zur erzeugung von analgesie und zur verstärkung von opiat-analgesie |
| GB9500691D0 (en) * | 1995-01-13 | 1995-03-08 | Smithkline Beecham Plc | Compounds |
| GB9515412D0 (en) | 1995-07-27 | 1995-09-27 | Pharmacia Spa | 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives |
| GB9518572D0 (en) | 1995-09-12 | 1995-11-15 | Smithkline Beecham Plc | Compounds |
| US5845454A (en) * | 1996-04-23 | 1998-12-08 | Malizia; John T. | Drop ceiling hanging system |
| AU6144098A (en) | 1997-02-14 | 1998-09-08 | Bayer Corporation | Amide derivatives as selective neuropeptide y receptor antagonists |
| US6117841A (en) * | 1997-05-30 | 2000-09-12 | Warner-Lambert Company | Substituted peptidylamine calcium channel blockers |
| DE19740110A1 (de) | 1997-09-12 | 1999-03-18 | Boehringer Ingelheim Pharma | Substituierte 1,2,3,4,5,6-Hexahydro-2,6-methano-3-benzazocin-10-ole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| GB9727523D0 (en) | 1997-12-31 | 1998-02-25 | Pharmacia & Upjohn Spa | Alpha-aminoamide derivatives useful as analgesic agents |
| AU3459999A (en) * | 1998-04-27 | 1999-11-16 | Warner-Lambert Company | Substituted diarylalkyl amides as calcium channel antagonists |
| US6011035A (en) * | 1998-06-30 | 2000-01-04 | Neuromed Technologies Inc. | Calcium channel blockers |
| US6316440B1 (en) * | 1998-07-30 | 2001-11-13 | Warner-Lambert Company | Reduced dipeptide analogues as calcium channel antagonists |
| US6472530B1 (en) * | 1999-09-22 | 2002-10-29 | Ortho-Mcneil Pharmaceutical, Inc. | Benzo-fused dithiepino[6,5-b]pyridines, and related compositions and methods |
| ATE266666T1 (de) * | 2000-03-23 | 2004-05-15 | Ortho Mcneil Pharm Inc | Thiepino(3,2-b)dihydropyridine und relatierte zusammensetzungen und verfahren |
| BR0109706A (pt) | 2000-03-31 | 2003-02-04 | Euro Celtique Sa | Aminopiridinas e seus usos como anticonvulsivantes e bloqueadores dos canais de sódio |
| US6521647B2 (en) * | 2000-04-04 | 2003-02-18 | Pfizer Inc. | Treatment of renal disorders |
| SE0102858D0 (sv) | 2001-08-27 | 2001-08-27 | Astrazeneca Ab | N-type calcium channel antagonists for the treatment of pain |
| ATE317280T1 (de) | 2001-09-03 | 2006-02-15 | Newron Pharm Spa | Pharmazeutische zusammensetzung mit gabapentin oder deren analog und einem alpha-aminoamid und analgetische verwendung dieser zusammensetzung |
| JP2005514412A (ja) | 2001-12-27 | 2005-05-19 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | 中枢神経系疾患を処置するために有用なアロイルピロールヘテロアリールおよびメタノール類 |
| EP1438956A1 (en) | 2003-01-16 | 2004-07-21 | Newron Pharmaceuticals S.p.A. | Alpha-aminoamide derivatives useful as antimigraine agents |
| WO2004087125A1 (en) * | 2003-04-02 | 2004-10-14 | Ionix Pharmaceuticals Limited | Amino acid derivatives as inhibitors of mammalian sodium channels |
| AR044007A1 (es) * | 2003-04-11 | 2005-08-24 | Newron Pharmaceuticals Inc | Metodos para el tratamiento de la enfermedad de parkinson |
| AU2004266494B2 (en) * | 2003-08-25 | 2010-04-08 | Newron Pharmaceuticals, Spa | Alpha-aminoamide derivatives useful as anti-inflammatory agents |
| EP1557166A1 (en) | 2004-01-21 | 2005-07-27 | Newron Pharmaceuticals S.p.A. | Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders |
| EP1588704A1 (en) | 2004-04-22 | 2005-10-26 | Newron Pharmaceuticals S.p.A. | Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders |
| SI1809271T1 (sl) | 2004-09-10 | 2010-10-29 | Newron Pharm Spa | Uporaba (R)-(halobenziloksi) benzilamino propanamidov kot selektivnih modulatorjev natrijevih in/ali kalcijevih kanalov |
| EP1963280B1 (en) * | 2005-12-22 | 2015-10-28 | Newron Pharmaceuticals S.p.A. | 2-phenylethylamino derivatives as calcium and/or sodium channel modulators |
| EP1870097A1 (en) | 2006-06-15 | 2007-12-26 | Newron Pharmaceuticals S.p.A. | Alpha-aminoamide derivatives useful in the treatment of cognitive disorders |
-
2008
- 2008-05-14 CA CA2689561A patent/CA2689561C/en active Active
- 2008-05-14 EP EP08749449.8A patent/EP2155663B1/en active Active
- 2008-05-14 CN CN200880020386.5A patent/CN101687773B/zh active Active
- 2008-05-14 AU AU2008261325A patent/AU2008261325B2/en active Active
- 2008-05-14 KR KR1020107001038A patent/KR101545124B1/ko active Active
- 2008-05-14 HU HUE08749449A patent/HUE038113T2/hu unknown
- 2008-05-14 NZ NZ581288A patent/NZ581288A/en unknown
- 2008-05-14 US US12/663,926 patent/US8519000B2/en active Active
- 2008-05-14 BR BRPI0813363A patent/BRPI0813363B8/pt active IP Right Grant
- 2008-05-14 PL PL08749449T patent/PL2155663T3/pl unknown
- 2008-05-14 ES ES08749449.8T patent/ES2655704T3/es active Active
- 2008-05-14 LT LTEP08749449.8T patent/LT2155663T/lt unknown
- 2008-05-14 JP JP2010511510A patent/JP5440496B2/ja active Active
- 2008-05-14 NO NO08749449A patent/NO2155663T3/no unknown
- 2008-05-14 PT PT87494498T patent/PT2155663T/pt unknown
- 2008-05-14 EA EA201070018A patent/EA018195B1/ru unknown
- 2008-05-14 WO PCT/EP2008/003848 patent/WO2008151702A1/en not_active Ceased
- 2008-05-14 DK DK08749449.8T patent/DK2155663T3/en active
- 2008-05-14 HR HRP20180324TT patent/HRP20180324T8/hr unknown
- 2008-05-14 TR TR2018/02576T patent/TR201802576T4/tr unknown
- 2008-05-14 RS RS20180061A patent/RS56780B1/sr unknown
- 2008-05-14 SI SI200831914T patent/SI2155663T1/en unknown
- 2008-05-14 MX MX2009013119A patent/MX2009013119A/es active IP Right Grant
- 2008-05-19 TW TW097118361A patent/TWI400071B/zh active
- 2008-06-13 AR ARP080102533A patent/AR068976A1/es active IP Right Grant
-
2009
- 2009-11-19 IL IL202235A patent/IL202235A/en active IP Right Grant
-
2013
- 2013-03-11 US US13/794,555 patent/US9051240B2/en active Active
- 2013-03-11 US US13/794,377 patent/US9248116B2/en active Active
-
2015
- 2015-02-05 US US14/614,758 patent/US9474737B2/en active Active
- 2015-02-05 US US14/615,275 patent/US9603832B2/en active Active
- 2015-02-05 US US14/615,176 patent/US9474738B2/en active Active
- 2015-02-05 US US14/615,227 patent/US9474739B2/en active Active
- 2015-02-05 US US14/614,677 patent/US9585869B2/en active Active
-
2018
- 2018-01-16 CY CY20181100053T patent/CY1119787T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010529969A5 (enExample) | ||
| HRP20180324T1 (hr) | Supstituirani derivati 2-[2-(fenil)etilamino]alkanamida i njihova upotreba kao modulatora natrijevih i/ili kalcijevih kanala | |
| ES2620446T3 (es) | Nuevo compuesto heterocíclico bicíclico | |
| JP2009526831A5 (enExample) | ||
| JP2011510014A5 (enExample) | ||
| JP2009513703A5 (enExample) | ||
| TW201329071A (zh) | 麩胺酸酶的雜環抑制劑 | |
| CN1155276A (zh) | 酶抑制剂 | |
| CN104010636B (zh) | 三环化合物、包含它们的组合物及其用途 | |
| JP2011527333A5 (enExample) | ||
| RU2009136592A (ru) | Терапевтические агенты | |
| CN102665417A (zh) | 用于治疗神经学上的功能失调的mglur4变构增效剂、组合物和方法 | |
| JP2013507426A5 (enExample) | ||
| TW201607539A (zh) | 加巴噴丁類似物和σ受體配體組合物 | |
| JP2013522368A5 (enExample) | ||
| JP2005522439A5 (enExample) | ||
| EP1906955A2 (en) | Use of thiazole derivatives and analogues in the treatment of cancer | |
| JP2015502371A5 (enExample) | ||
| ME02524B (me) | Fluorisani derivati arilalkilaminokarboksamida | |
| HRP20140326T1 (hr) | Derivat aromatiäśnog 6-äślanog prstena koji sadrži dušik i farmaceutsko sredstvo koje sadrži taj derivat | |
| JP2009521417A5 (enExample) | ||
| TWI441631B (zh) | 有效於治療精神障礙之α－胺基醯胺衍生物 | |
| CN103781771A (zh) | 苯并噻唑酮化合物 | |
| JP2007516292A5 (enExample) | ||
| KR20180100627A (ko) | 섬망의 예방 또는 치료제 |